Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhen Qiu

Showing results (471-480 of 474) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 474 results.
Plos Medicine|May 10, 2024
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trialDe-Shen Wang, Chao Ren, Shan-Shan Li, et al.
Cancer Communications (London, England)|July 1, 2021
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021Feng-Hua Wang, Xiao-Tian Zhang, Yuan-Fang Li, et al.
Cancer Communications (London, England)|December 31, 2023
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, et al.
Nature Medicine|July 16, 2025
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trialDan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, et al.
Pageof 48

Showing results (471-480 of 474) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 474 results.
Plos Medicine|May 10, 2024
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trialDe-Shen Wang, Chao Ren, Shan-Shan Li, et al.
Cancer Communications (London, England)|July 1, 2021
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021Feng-Hua Wang, Xiao-Tian Zhang, Yuan-Fang Li, et al.
Cancer Communications (London, England)|December 31, 2023
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, et al.
Nature Medicine|July 16, 2025
The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trialDan-Yun Ruan, Hao-Xiang Wu, Su-Xia Luo, et al.
Pageof 48